Three generations of a Brisbane family have played a crucial role in a groundbreaking study that has identified a new genetic mutation linked to ulcerative colitis, a debilitating inflammatory bowel disease. This discovery, made by researchers at Mater Hospital in South Brisbane, could pave the way for new treatments and improved understanding of the condition.
The family, comprising a grandmother, two of her children, and two grandchildren, have all been diagnosed with ulcerative colitis, which causes inflammation and ulcers in the large intestine and rectum. The severity of the condition has led to four family members undergoing surgery at a young age, with one as young as 14, to remove parts of their bowels. All have been treated at the Mater Hospital, highlighting the hospital’s role in this significant medical breakthrough.
Genetic Mutation Discovery
Using advanced genomic sequencing, researchers compared the DNA of family members with ulcerative colitis to those without the condition. This comparison led to the identification of a mutation in the OTUD3 gene, which is now linked to the disease. Dr. Rabina Giri, the lead researcher from Mater Research’s Inflammatory Bowel Disease Group, emphasized the significance of this finding, marking the first time the OTUD3 gene has been associated with intestinal health.
“We’ve known this gene plays a role in cancer biology, but now we’ve shown it’s essential for maintaining the integrity of the gut lining,” Dr. Giri stated.
Collaboration and Broader Implications
Dr. Giri’s research was conducted in collaboration with experts from the University of Queensland, Monash University, and international partners at Harvard Medical School and Mass General Brigham in Boston. Over seven years, the team studied the gene using data from UK and Finnish biobanks, discovering that the OTUD3 mutation is present not only in the Brisbane family but also in a significant number of other ulcerative colitis patients.
Further investigation revealed that even in patients without the mutation, OTUD3 dysfunction was evident. Dr. Giri speculated that other genetic factors or gut inflammation might influence the gene’s activity. The research raises hopes for new drug developments targeting the OTUD3 gene to treat ulcerative colitis.
“If we can find a drug that can upregulate the protein expression, that might be a good treatment strategy,” Dr. Giri explained, noting preliminary data suggesting some existing drugs could increase expression.
Future Research and Treatment Prospects
The research team is seeking additional funding to explore the potential of repurposing drugs used for other conditions to treat ulcerative colitis. Environmental factors, such as a high-sugar Western diet, are also being investigated for their role in triggering the disease in genetically susceptible individuals.
Dr. Giri highlighted that about 0.1% of people of South Asian descent, like the Brisbane family, carry the OTUD3 mutation, although not all develop ulcerative colitis. The study has already facilitated early diagnosis and successful treatment of a young family member using anti-tumor necrosis factor (TNF) drugs, which have stabilized his condition since 2021.
Expert Opinions and Broader Impact
Gastroenterologist Jake Begun, who leads Mater Research’s Inflammatory Bowel Disease Research Group, emphasized the importance of genetic research in uncovering hidden causes of chronic diseases. He noted that the discovery opens new avenues for diagnostic tools and therapies that target the gut lining rather than just the immune system.
Griffith University professor of pathology Albert Lam, who was not involved in the study, described the findings as “significant” for highlighting the bowel barrier’s role in ulcerative colitis.
“This is a very important discovery,” Professor Lam remarked. “It can be a channel for us to drive into a more useful therapy for this kind of patient.”
Professor Lam stressed the need for extensive research to test new diagnostic tools and treatments on large patient samples to ensure their effectiveness. The study’s publication in the journal Cellular and Molecular Gastroenterology and Hepatology underscores its scientific impact.
Conclusion and Next Steps
With over 100,000 Australians estimated to be living with inflammatory bowel disease, this study represents a significant step forward in understanding and potentially treating ulcerative colitis. The research team’s ongoing efforts to explore genetic and environmental factors could lead to more personalized and effective treatment strategies, offering hope to patients worldwide.
